Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Rezdiffra has interactions with certain drugs, such as clopidogrel, atorvastatin, and gemfibrozil. Talk with your doctor to avoid potentially harmful effects from Rezdiffra interactions.

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain my Hold rating on MDGL stock.

Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if ...

The most common side effects of Rezdiffra include: diarrhea, nausea, itching, stomach (abdominal) pain, vomiting, dizziness, constipation. These are not all the possible side effects of Rezdiffra.

Rezdiffra is not approved in Europe for the treatment of patients with MASH with moderate to advanced liver fibrosis and not approved in any geography for the treatment of patients with cirrhosis.

What is Rezdiffra? Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), ...

About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in ...

Madrigal on Friday said a green light would make Rezdiffra the first medication approved in the E.U. for MASH, which is the fastest-growing indication for liver transplantation in Europe.

Rezdiffra is already approved and available in the US for adults with noncirrhotic MASH who have moderate to advanced liver fibrosis. If approved in Europe, Rezdiffra would hold the same indication.